The administration of granulocyte colony-stimulating factor (G-CSF) to increase the white blood cell count in granulocyte donors prior to donation is becoming an increasingly common practice. G-CSF is given subcutaneously to the donor on the day prior to donation, generally 12 to 24 hours before the start of apheresis. G-CSF has also been given for 5 days to hematopoietic stem cells donors prior collecting peripheral blood stem cell(PBSC)concentrates by apheresis. PBSC concentrate donors given G-CSF experience splenic enlargement and rarely, spontaneous rupture of the spleen. This study evaluated the incidence and time course of splenic enlargement in PBSC concentrate donors and accessed factors effecting size changes. Twenty healthy adult PBSC concentrate donors were given G-CSF (10 mg/kg/day) for 5 days. Ultrasound was used to assess craniocaudal spleen length prior to giving G-CSF, the day of apheresis, and 3 or 4 days after apheresis. The effects of donor age, gender, race and changes in blood chemistries, blood counts, and CD34+ cell counts on spleen length change was assessed. Spleen length increased in 19 of 20 donors. Mean length changed from 10.7 cm pre-G-CSF to 12.3 cm on the apheresis day (p < 0.002). Three or four days after apheresis the spleen length fell to 11.3 cm (p<0.001), but remained greater than baseline levels (p=0.04). There was no difference in spleen length change among males and females or among Caucasians and non-Caucasians. There was no relationship between subject age and change in length or percent change in length. There was no relationship between baseline blood counts and chemistries and change in apheresis day size but apheresis day alkaline phosphatase and total bilirubin levels were related to change in length. These studies found that spleen size increases in almost all PBSC donors. Enlargement is transient but marked in some donors and may place donors at risk for splenic rupture. Greater collection day alkaline phosphatase, bilrubin and neutrophil levels were associated with greater increases in spleen size. Future studies will focus on identifying factors that predict which donor will have a very large increase in spleen size.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL002099-04
Application #
6683849
Study Section
(DTM)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Jin, Ping; Wang, Ena; Ren, Jiaqiang et al. (2008) Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 6:39
Stroncek, David F; Jin, Ping; Wang, Ena et al. (2007) Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med 5:24
Ren, Jiaqiang; Jin, Ping; Wang, Ena et al. (2007) Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transl Med 5:1
Stroncek, David; Slezak, Stefanie; Khuu, Hanh et al. (2005) Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol 33:1109-17
Stroncek, David; Dittmar, Kristin; Shawker, Thomas et al. (2004) Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2:25
Stroncek, David; Shawker, Thomas; Follmann, Dean et al. (2003) G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 43:609-13
Stroncek, David F; Matthews, Cynthia L; Follmann, Dean et al. (2002) Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 42:597-602
Stroncek, D F; Confer, D L; Leitman, S F (2000) Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 40:731-41